Sigachi Industries Past Earnings Performance
Past criteria checks 4/6
Sigachi Industries has been growing earnings at an average annual rate of 19.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 22.1% per year. Sigachi Industries's return on equity is 13.5%, and it has net margins of 15%.
Key information
19.4%
Earnings growth rate
-18.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 22.1% |
| Return on equity | 13.5% |
| Net Margin | 15.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sigachi Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,408 | 661 | 639 | 0 |
| 30 Jun 24 | 4,100 | 595 | 595 | 0 |
| 31 Mar 24 | 4,041 | 572 | 579 | 0 |
| 31 Dec 23 | 3,672 | 495 | 548 | 0 |
| 30 Sep 23 | 3,251 | 432 | 508 | 0 |
| 30 Jun 23 | 3,084 | 416 | 436 | 0 |
| 31 Mar 23 | 3,020 | 435 | 391 | 0 |
| 31 Dec 22 | 3,022 | 479 | 324 | 0 |
| 30 Sep 22 | 2,989 | 476 | 265 | 0 |
| 30 Jun 22 | 2,736 | 439 | 218 | 0 |
| 31 Mar 22 | 2,503 | 400 | 220 | 0 |
| 31 Dec 21 | 2,325 | 376 | 202 | 0 |
| 30 Sep 21 | 2,152 | 351 | 217 | 0 |
| 30 Jun 21 | 2,044 | 323 | 210 | 0 |
| 31 Mar 21 | 1,958 | 303 | 181 | 0 |
| 31 Mar 20 | 1,427 | 203 | 155 | 0 |
| 31 Mar 19 | 1,323 | 190 | 127 | 0 |
| 31 Mar 18 | 1,027 | 69 | 93 | 0 |
Quality Earnings: 543389 has a high level of non-cash earnings.
Growing Profit Margin: 543389's current net profit margins (15%) are higher than last year (13.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543389's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: 543389's earnings growth over the past year (53.1%) exceeds its 5-year average (19.4% per year).
Earnings vs Industry: 543389 earnings growth over the past year (53.1%) exceeded the Pharmaceuticals industry 20%.
Return on Equity
High ROE: 543389's Return on Equity (13.5%) is considered low.